https://csf-1r-receptor.com/in....dex.php/polymeric-mi
Of 766 addressed customers enrolled, 59.5% had been male, 94.8% had an Eastern Cooperative Oncology Group overall performance status of 0-1, all gotten previous chemotherapy (97.8% including oxaliplatin), and 58.6% had prior publicity to bevacizumab. A minumum of one grade ≥ 3 treatment-emergent adverse event (TEAE) had been reported in 68.3% of patients. Neutropenia, high blood pressure, diarrhea, and asthenia had been the most
Like
Comment
Share
